X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (3y) (2020 - 2025)
X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 32.17% |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn | 52.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52.56% |
| Sep 30, 2025 | -2.33% |
| Jun 30, 2025 | 60.20% |
| Mar 31, 2025 | -0.46% |
| Dec 31, 2024 | -112.06% |
| Sep 30, 2024 | -38.83% |
| Jun 30, 2024 | 66.66% |
| Mar 31, 2024 | -45.47% |
| Dec 31, 2023 | -47.24% |
| Sep 30, 2023 | -51.71% |
| Jun 30, 2023 | 51.13% |
| Mar 31, 2023 | -37.17% |
| Dec 31, 2022 | -6.67% |
| Sep 30, 2022 | 55.75% |
| Jun 30, 2022 | -31.24% |
| Mar 31, 2022 | -44.79% |
| Dec 31, 2021 | 73.54% |
| Sep 30, 2021 | -90.55% |
| Jun 30, 2021 | -47.66% |
| Mar 31, 2021 | 87.61% |